Médecine

Paramédical

Autres domaines


S'abonner

Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons - 09/09/11

Doi : 10.1016/S0190-9622(98)70159-8 
Brian Berman, MD, PhDa, Francisco Flores, MDa, George Burke, MDb
Miami, Florida 
From the Department of Dermatology and Cutaneous Surgerya and Surgery,b University of Miami School of Medicine 

Abstract

Background: Pruritic papular eruption (PPE) of HIV/AIDS is a common manifestation of HIV infection. Unfortunately, treatments for the unremitting pruritus have yielded only partial relief. Objective: Our purpose was to assess the clinical efficacy of pentoxifylline in the treatment of pruritus in HIV-infected patients with PPE while measuring its effects on HIV viral load and levels of serum triglycerides, tumor necrosis factor (TNF)–⍺, and interleukin (IL)-4. Methods: Eleven of the 12 patients with PPE and HIV infection placed on a regimen of oral pentoxifylline completed the 8-week study. The degree of pruritus both before and after therapy was measured by means of a patient-reported visual analog scale (0 = none and 10 = worst experienced). A global assessment of the number and size of PPE lesions was performed by the investigator, and serum TNF-⍺, IL-4, and triglyceride levels, as well as HIV viral load, were measured. Results: The average degree of pruritus was significantly reduced (p = 0.0009) from 6.5 at baseline examination to 3.6 at the end of the study. Ten of 11 patients experienced a reduction in their pruritus, ranging from 22.6% to 87.3%. The global assessment of PPE lesions decreased from baseline in most patients and increased slightly in one patient. Serum TNF-⍺ was detectable in one patient at baseline, but was undetectable at the end of the study period. Similarly, the two patients who had detectable serum IL-4 at baseline had undetectable serum IL-4 levels at the end of the study. Triglyceride levels in six patients decreased an average of 23.9% by week 8. Although when compared with baseline values, HIV viral loads in seven patients decreased, one patient had no change, and three patients had an increase in their viral load at the end of the study, the magnitude of the changes were of little clinical importance. Conclusion: Pentoxifylline is a safe and efficacious treatment of pruritus in HIV-infected patients with PPE. Future controlled studies are needed to confirm the effectiveness of this treatment. (J Am Acad Dermatol 1998;38:955-9.)

Le texte complet de cet article est disponible en PDF.

Plan


 Reprint requests: Brian Berman, MD, PhD, University of Miami School of Medicine, Department of Dermatology and Cutaneous Surgery, 1600 NW 10th Ave., Room 2023A, Miami, FL 33136.
 0190-9622/98/$5.00 + 0  16/1/90018


© 1998  American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 38 - N° 6

P. 955-959 - juin 1998 Retour au numéro
Article précédent Article précédent
  • Analysis of vascularity of human neurofibromas
  • Jack L. Arbiser, Evelyn Flynn, Raymond L. Barnhill
| Article suivant Article suivant
  • Squamous cell carcinoma of the lip treated with Mohs micrographic surgery: Outcome at 5 years
  • Kristina A. Holmkvist, Randall K. Roenigk

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.